@article{6a8f9e264a5947978845bf5f3c2950af,
title = "Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project",
abstract = "ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.",
keywords = "Alzheimer's disease, data sharing, data systems, health policy, patient outcome assessment, real-world clinical trials, systems integration, FRAMEWORK, DEMENTIA, TRIALS",
author = "John Gallacher and {de Vulpillieres}, {Frederic de Reydet} and Billy Amzal and Zuzanna Angehrn and Christin Bexelius and Christophe Bintener and Bouvy, {Jacoline C.} and Laura Campo and Carlos Diaz and Jean Georges and Alastair Gray and Antje Hottgenroth and Pall Jonsson and Brent Mittelstadt and Potashman, {Michele H.} and Catherine Reed and Cathie Sudlow and Robin Thompson and Antje Tockhorn-Heidenreich and Andrew Turner and {van der Lei}, Johan and Visser, {Pieter Jelle} and {ROADMAP consortium}",
note = "Funding Information: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation program and EFPIA. It is also supported by the Medical Research Council Dementias Platform UK (MR/L023784/1 and MR/009076/1). The authors would like to acknowledge Dr. Sue Chambers and Karen Goa (Rx Communications, Mold, UK) for medical writing assistance with the preparation of this manuscript, funded by Eli Lilly and Company. They would also like to acknowledge the ROADMAP contributors: University of Oxford, UK; National Institute for Health and Care Excellence (NICE), UK; Erasmus Universitair Medisch Centrum Rotterdam, the Netherlands; Universiteit Maastricht, the Netherlands; Synapse Research Management Partners SL, Spain; Fundaci{\'o} Institut Universitari per a la Recerca a l{\textquoteright}Atenci{\'o} Prim{\`a}ria de Salut Jordi Gol i Gurina, Spain; K{\o}benhavns Universitet, Denmark; Alzheimer Europe, Luxembourg; University of Edinburgh, UK; Goeteborgs Universitet, Sweden; Aarhus Universitet, Denmark; London School of Economics and Political Science, UK; Agentschap College ter Beoordeling van Geneesmiddelen/Medicines Evaluation Board, the Netherlands; IXICO Technologies Ltd, UK; Rijk-suniversiteit Groningen, the Netherlands; Novartis Pharma AG, Switzerland; Eli Lilly and Company Ltd, UK; Biogen Idec Ltd, UK; F. Hoffmann-La Roche Ltd, Switzerland; Janssen Pharmaceutica NV, Belgium; GE Healthcare Ltd, UK; AC Immune SA, Switzerland; Takeda Development Centre Europe Ltd, UK; H. Lundbeck A/S, Denmark; Leids Uni-versitair Medisch Centrum, the Netherlands; Centre Hospitalier Universitaire de Bordeaux, France. Publisher Copyright: {\textcopyright} 2019 IOS Press and the authors. All rights reserved.",
year = "2019",
doi = "10.3233/JAD-180370",
language = "English",
volume = "67",
pages = "495--501",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",
}